ABSTRACT
Purpose
Bioreducible crosslinked polyplexes were prepared via disulfide bond formation after siRNA condensation with polyethylenimine-modified by deoxycholic acid (PEI-DA) to stabilize polyplex structure in an extracellular environment and to promote transfection efficiency in human smooth muscle cells (hSMCs).
Methods
The PEI-DA/siRNA polyplexes were further modified by crosslinking the primary amines of PEI with thiol-cleavable crosslinkers. The effect of disulfide crosslinked PEI-DA/siRNA (Cr PEI-DA/siRNA) polyplexes on target gene silencing was investigated by transfecting hSMCs with matrix metalloproteinase-2 (MMP-2) siRNA under serum conditions. The MMP-2 levels in the conditioned medium were examined using gelatin zymography.
Results
The Cr PEI-DA/siRNA polyplexes showed increased stability against heparin exchange reactions, while their disulfide linkages were successfully cleaved under reducing conditions. The polyplex crosslinking reaction led to a slight decrease in MMP-2 gene silencing activity in hSMCs due to the insufficient redox potential. However, the gene silencing efficiency of the Cr PEI-DA/siRNA polypexes was gradually improved in response to increasing intracellular reduction potential. The increased serum stability of the Cr PEI-DA/siRNA polyplexes resulted in significant enhancement of the intracellular delivery efficiency especially under serum conditions.
Conclusion
The Cr PEI-DA/siRNA polyplex formulation may be a promising siRNA delivery system for the treatment of incurable genetic disorders.
Similar content being viewed by others
REFERENCES
McManus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet. 2002;3:737–47.
Jeong JH, Park TG, Kim SH. Self-assembled and nanostructured siRNA delivery systems. Pharm Res. 2011;28:2072–85.
Castanotto D, Rossi JJ. The promises and pitfalls of RNA interference-based therapeutics. Nature. 2009;457:426–33.
Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;8:129–38.
Gao X, Kim K-S, Liu D. Nonviral gene delivery: what we know and what is next. AAPS J. 2007;23:E92–E104.
Park KH, Yun CO, Kwon OJ, Kim CH, Kim JR, Cho KH. Enhacned deliery of adenovirus, using proteoliposomes containing wildtype or V156K apolipoprotein A-1 and dimyristoylphosphatidylcholine. Hum Gene Ther. 2010;21:597–87.
Kim SH, Jeong JH, Lee SH, Kim SW, Park TG. PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J Control Release. 2006;116:123–9.
Mao S, Neu M, Germershaus O, Merkel O, Sitterberg J, Bakowsky U, et al. Influence of polyethylene glycol chain length on the physicochemical and biological properties of poly(ethylene imine)-graft-poly(ethylene glycol) block copolymer/siRNA polyplexes. Bioconjugate Chem. 2006;17:1209–18.
Christie RJ, Nishiyama N, Kataoka K. Minireview: delivering the code: polyplex carriers for deoxyribonucleic acid and ribonucleic acid interference therapies. Endocrinology. 2010;15:466–73.
Khalil IA, Kogure K, Akita H, Harashima H. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol Rev. 2006;58:32–45.
Kim SH, Jeong JH, Lee SH, Kim SW, Park TG. PEG local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J Control Release. 2008;129:107–16.
Gary DJ, Puri N, Won YY. Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polyer-based DNA delivery. J Control Release. 2007;121:64–73.
Oupicky D, Parker AL, Seymour LW. Laterally stabilized compleses of DNA with linear reducible polycations: strategy for triggered intracellular activation of DNA delivery vectors. J Am Chem Soc. 2002;124:8–9.
Neu M, Sitterberg J, Bakowsky U, Kissel T. Stabilized nanocarriers for plasmids based upon cross-linked poly(ethylene imine). Biomacromolecules. 2006;7:3428–38.
Fischer D, Bieber T, Li Y, Elsässer H, Kissel T. A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity. Pharm Res. 1999;16:1273–9.
Chae SY, Kim HJ, Lee MS, Jang YL, Lee Y, Lee SH, et al. Energy-independent intracellular gene delivery mediated by polymeric biomimetics of cell-penetrating peptides. Macromol Biosci. 2011;11:1169–74.
Mikov M, Fawcett JP, Kuhajda K, Kevresan S. Pharmacology of bile acids and their derivatives: absorption promoters and therapeutic agents. Eur J Drug Metabol Pharmacokinet. 2006;31:237–51.
Ferreira LF, Gilliam LAA, Reid MB. L-2-Oxothiazolidine-4-carboxylate reverses glutathione oxidation and delays fatigue of skeletal muscle in vitro. J Appl Physiol. 2009;107:211–6.
Babu E, Ananth S, Veerrannan-Karmegam R, Coothankandaswamy V, Smith SB, Boettger T, et al. Transport via SLC5A8 (SMCT1) is obligatory for 2-oxothiazolidine-4-carboxylate to enhance glutathione production in retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2011;52:5749–57.
Kim D, Lee D, Jang YL, Chae SY, Choi D, Jeong JH, et al. Facial amphipathic deoxycholic acid-modified polyethyleneimine for efficient MMP-2 siRNA delivery in vascular smooth muscle cells. Eur J Pharm Biopharm. 2012, doi:10.1016/j.ejpb.2012.01.013.
Mok H, Lee SH, Park JW, Park TG. Multimeric small interfering ribonucleic acid for highly efficient sequence-specific gene silencing. Nat Mater. 2010;9:272–8.
Kim SH, Jeong JH, Kim T, Kim SW, Bull DA. VEGF siRNA delivery system using arginine-grafted bioreducible poly(disulfide amine). Mol Pharm. 2009;6:718–26.
Wang W, Ballatori N. Endogenous glutathione conjugates: occurrence and biological functions. Pharmacol Rev. 1998;50:335–56.
Bauhuber S, Hozsa C, Breunig M, Gopferich A. Delivery of nucleic acids via disulfide-based carrrier systems. Adv Mater. 2009;21:3286–306.
Kish PE, Tsume Y, Kijek P, Lanigan TM, Hilfinger JM, Roessler BJ. Bile acid-oligopeptide conjugates interact with DNA and facilitate transfection. Mol Pharm. 2007;4:95–103.
Katsaros KM, Kastl SP, Zorn G, Maurer G, Wojta J, Huber K, et al. Increased restenosis rate after implantation of drug-eluting stents in patients with elevated serum activity of matrix metalloproteinase-2 and -9. JACC Cardiovasc Interv. 2010;3:90–7.
Kuzuya M, Kanda S, Sasaki T, Tamaya-Mori N, Cheng XW, Itoh T, et al. Deficiency of gelatinase a suppresses smooth muscle cell invasion and development of experimental intimal hyperplasia. Circulation. 2003;108:1375–81.
Giorgi G, Micheli L, Fiaschi AI, Cerretani D, Romeo R, Dal Pra P, et al. L-2-oxothiazolidine-4-carboxylic acid and glutathione in human immunodeficiency virus. Curr Ther Res. 1992;52:461–7.
Williamson JM, Boettcher B, Meister A. Intracellular cysteine delivery system that protects against toxicity by promoting glutathione synthesis. Proc Natl Acad Sci USA. 1982;79:6246–9.
Paula DD, Bentley MVLB, Mahato RI. Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA. 2007;13:431–56.
Oupicky D, Carlisle RC, Seymour LW. Triggered intracellular activation of disulfide crosslinked polyelectrolyte gene delivery complexes with extended systemic circulation in vivo. Gene Ther. 2001;8:713–24.
ACKNOWLEDGMENTS & DISCLOSURES
This work was supported by a grant from the Korea Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A110879).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Lee, D., Kim, D., Mok, H. et al. Bioreducible Crosslinked Polyelectrolyte Complexes for MMP-2 siRNA Delivery into Human Vascular Smooth Muscle Cells. Pharm Res 29, 2213–2224 (2012). https://doi.org/10.1007/s11095-012-0750-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-012-0750-4